Wave Life Sciences Ltd. 2026年度季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES For the quarterly period ended March 31, 2026 For the transition period from ______ to ______Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer,’’ ‘‘smaller reporting company,’’ and If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ The number of outstanding ordinary shares of the registrant as of April 22, 2026 was 192,379,977. PART I - FINANCIAL INFORMATION PART II - OTHER INFORMATION Item 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. Exhibits Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Actof 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”), that relate to future events or to our future operations or financial performance. Any forward-looking statement involvesknown and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance orachievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied bysuch forward-looking statement. In some cases, forward-looking statements are identified by the words “anticipate,” “believe,”“continue,” “could,” “estimate,” “expect,” “future,” “goals,” “intend,” “likely,” “may,” “might,” “ongoing,” “objective,” “plan,”“potential,” “predict,” “project,” “seek,” “should,” “strategy,” “target,” “will” and “would” or the negative of these terms, or othercomparable terminology intended to identify statements about the future, although not all forward-looking statements contain theseidentifying words. Forward-looking statements include statements, other than statements of historical fact, about, among otherthings:our ability to fund our future operations; our financial position, revenues, costs, expenses, uses of cash and capitalrequirements; our need for additional financing or the period for which our existing cash resources will be sufficient to meet ouroperating requirements; the success, progress, number, scope, cost, duration, timing or results of our research and developmentactivities, preclinical studies and clinical trials, including the timing for initiation or completion of or availability of results from any Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you thatthese statements are based on our estimates or projections of the future that are subject to known and unknown risks anduncertainties and other important factors that may cause our actual results, level of activity, performance or achievements expressedor implied by any forward-looking statement to differ. These risks, uncertainties and other factors include, among other things, ourcritical accounting policies; the ability of our preclinical studies to produce data sufficient to support the filing of global clinical trialapplications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed toachieve our goals; the clinical results and timing of our programs, which may not support further development of our productcandidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness inmanaging current and future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; thecontinued development and acceptance of nucleic acid therapeutics as a class of drugs;